|
||
| |||||||
|
|
Dr Ehmer, CEO of BioPheresis
Technologies, brings 20 years of clinical R&D and business management
experience from the pharma industry
Paris, August 3rd, 2006 -
Hybrigenics, the protein pathway-based cancer drug discovery and development
company, announces today the appointment of Bernhard R M Ehmer, MD, to its
supervisory board as a non-executive independent Director.
"We are delighted to welcome Dr
Bernhard Ehmer to our Board of Directors, as he brings a wealth of
international experience in clinical development and pharmaceutical marketing
in oncology," said Rémi Delansorne, Hybrigenics' CEO. "Bernhard's
know-how in bringing anticancer molecules to market will be of tremendous help
for Hybrigenics' R&D activities."
Dr Bernhard Ehmer, 51, is
currently CEO of BioPheresis Technologies Inc, a US company focused on the
development and commercialization of a patent protected system (OncoSorb(R))
for the immunological treatment of cancer patients, with operational
headquarters based in Heidelberg, Germany. At Merck KGaA, Dr Ehmer was
successively Head of Clinical R&D Operations (1998-2000), Vice-President for
the Business Area Oncology (2000-2005) and for Corporate Strategic Planning
and Alliance Management (2005). His leadership played a key role in the
development, registration and launch by Merck KgaA of cetuximab (Erbitux(R)),
a chimeric monoclonal antibody targeting the EGF receptor from Imclone, for
cancer indications outside North America. He also mastered a cooperation
agreement with Takeda on matuzumab, a humanized monoclonal antibody against
EGFR, developed by Merck KGaA.
Before joining Merck KGaA, Dr
Ehmer spent 12 years with Boehringer Mannheim GmbH in various clinical R&D and
management positions in Germany, Italy and Singapore. Among his major
achievements was the extension of the therapeutic indications of recombinant
erythropoietin to the supportive treatment of cancer.
Dr Ehmer was resident in Internal
Medicine at a teaching hospital of the University of Heidelberg from 1983 to
1986, after having graduated from the universities of Munich and Heidelberg
(1976-1982). He is the author or co-author of about 60 scientific articles and
co-editor of a book on the use of recombinant erythropoietin in cancer (1996).
About Hybrigenics:
http://www.hybrigenics.com
Hybrigenics is a biotechnology
company dedicated to the discovery of molecules active against targets
validated using the company's proprietary proteomics and bioinformatics
technologies. The company is carrying out its own research programs by
screening chemical libraries of small organic molecules against validated
targets in oncology. In addition, Hybrigenics is actively developing
inecalcitol, a vitamin D analogue, for cancer indications.
Hybrigenics also offers research services through access to its Yeast Two-Hybrid (Y2H) Screening platform and bioinformatics-based analysis of protein-protein interactions. Its fee-for-service activities have received ISO 9001:2000 certification. Its customers are public and private laboratories involved in the identification and validation of targets in all biological or therapeutic areas. For more information, please contact: |
|
| ||||||||